Monitoring Agency Report for the Quarter ended 31st March 2025
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bajaj Healthcare has filed the Monitoring Agency Report from CARE Ratings for Q4 FY25, covering its Rs. 204.97 crore Preferential Issue of equity shares and convertible warrants carried out in August–September 2024 at Rs. 338 per share. The issue was slightly undersubscribed — only 39.84 lakh shares were allotted against 40.44 lakh offered, trimming proceeds from Rs. 207 crore to Rs. 204.97 crore. So far, the company has called and received Rs. 152.26 crore (100% equity money plus 25% warrant money), which has been fully utilised: Rs. 150 crore toward repayment/prepayment of bank and NBFC loans (completed) and Rs. 2.25 crore for general corporate purposes. The remaining Rs. 52.71 crore (75% balance on warrants) is to be called within 18 months of the September 19, 2024 allotment. Deployment of the Rs. 35 crore earmarked for capital expenditure is ongoing with no utilisation yet. There are no material deviations from the stated objects, and CARE has confirmed utilisation is in line with disclosures.
This is a routine SEBI compliance filing and largely neutral for shareholders — it confirms that funds raised from the preferential issue are being used as promised, with the loan repayment leg already completed. The pending Rs. 52.71 crore from warrant conversions due over the next ~15 months will further bolster the balance sheet and support the still-pending Rs. 35 crore capex plan.